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bstructive sleep apnoea (OSA) is a 
complex condition associated with 
a number of cardiovascular 
sequelae including hypertension (both 
systemic and pulmonary), congestive heart 
failure, arrhythmias, myocardial infarction 
and stroke [1-6]. However, the recent 
American Heart Association/American 
College of Cardiology scientific statement 
on sleep apnoea suggests that there is a 
paucity of data for a causal role of OSA in 
cardiovascular disease [7] which 
underlines the importance of studies such 
as that of Akinnusi and co-workers in this 
edition of Respiration that are aimed at 
understanding the pathophysiology of OSA 
[8]. The condition is caused by multiple 
episodes of airway collapse during the 
course of sleep which causes large 
oscillations in intrathoracic pressure and in 
arterial blood gases. It is well known that 
chronic continuous hypoxia can cause 
changes in coagulation and in platelet 
number and function [9] and that changes 
in platelet function are associated with 
adverse cardiovascular effects [10]. 
Recently, it has been shown in rats that 
platelet activation can occur also when the 
hypoxia is intermittent [11]. Taken 
together, this provides good reason to 
suspect that alterations in platelet function 
as a consequence of the intermittent 
hypoxia of sleep apnoea may underlie 
some of the adverse cardiovascular effects 
associated with the condition. In support of 
this hypothesis, Akinnusi and co-workers 
demonstrate that there are elevated plasma 
sCD40L levels and platelet-monocyte 
aggregates in sleep apnoea patients and 
that this is correlated with hypoxia severity 
and that these effects are ameliorated by 
continuous positive airway pressure 
(CPAP), a treatment that relieves the 
obstruction and the hypoxia [8]. Previous 
studies did not find any effect on platelet 
aggregation in sleep apnoea patients 
[12,13] but several other studies have 
reported increased platelet activation and 
aggregation [14-18]. More recently, similar 
to Akinnusi and co-workers findings, an 
increase in sCD40L levels in sleep apnoea 
patients that was decreased by CPAP has 
been reported in two separate studies 
[5,19] with both studies showing a positive 
correlation with hypoxia severity.   
 
To our knowledge, platelet number was 
not measured in any of these studies except 
for that of Minoguchi and co-workers [5] 
in which there was no difference in 
number compared to obese controls. 
Chronic continuous hypoxia is known to 
cause an early thrombocytosis and a 
subsequent thrombocytopaenia. In just one 
study, chronic intermittent asphyxia in rats 
had no effect on platelet number [11].  
 
CD40L is a transmembrane protein and a 
member of the TNF family and also exists 
in a soluble form (sCD40L) in plasma 
which originates from activated platelets 
[20]. The interaction of CD40L with its 
receptor CD40 plays a major role in 
inflammation and increased levels of 
sCD40L are known to be associated with 
increased risk of cardiovascular events 
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[21,22] and is also known to play a role in 
the pathogenesis of atherosclerosis [23,24]. 
However, as the primary source of 
sCD40L is activated platelets, sCD40L 
also acts as a biomarker of platelet 
activation and platelet activation is itself 
associated with increased risk of 
cardiovascular disease [25,26]. Once 
activated, platelets secrete over 300 
biologically active proteins [27], any of 
which may play a role in the pathogenesis 
of cardiovascular disease, as well as 
forming platelet aggregates which cause 
the vessel occlusion associated with 
myocardial infarction. The study of 
Akinnusi and co-workers shows an 
association between sCD40L and sleep 
apnoea but it provides no evidence of a 
role for sCD40L in the pathogenesis of 
cardiovascular disease in these patients 
where it may simply be a biomarker of 
platelet activation. 
 
Recently CPAP has been shown to 
improve endothelial function [28] and to 
reduce blood pressure [29,30], sympathetic 
tone [31] and platelet activation [8,18] in 
patients with OSA. Thus, CPAP clearly 
reduces many of the risk factors for 
adverse cardiac events although the exact 
mechanism is not clear. Norman and co-
workers showed that while CPAP reduced 
blood pressure, nocturnal continuous 
oxygen therapy did not, even though it 
raised haemoglobin oxygen saturation 
levels, suggesting that a mechanism other 
than hypoxia may be involved [29]. It is 
not clear from the platelet studies whether 
a similar situation exists. Thus, while 
CPAP improves sleep and reduces daytime 
drowsiness [32], it also improves many of 
the underlying risk factors for 
cardiovascular disease. 
 
The work of Akinnusi et al has added to 
the body of evidence for a role for platelet 
activation in the cardiovascular disease 
associated with sleep apnoea and suggests 
that CPAP can decrease this platelet 
activation and therefore may improve both 
quality and duration of the life of OSA 
patients.  
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